BRUSSELS - The European Commission said on Wednesday it had sealed a deal with US pharmaceutical giant Pfizer and German company BioNTech for the supply of up to 300 million doses of their COVID-19 vaccine candidate.
Under the EU deal, the 27 EU countries could buy 200 million doses, and have an option to purchase another 100 million.
The move follows Pfizer’s announcement on Monday that its experimental vaccine developed with BioNTech was more than 90 percent effective, making them the first drugmakers to show successful interim data from a large-scale clinical trial of a coronavirus vaccine.
The two companies said that already next week they might seek from the US Food and Drug Administration (FDA) an emergency authorization of their coronavirus vaccine.
Vaccine doses will be distributed among the 27 EU member states based on the size of each country's population. However, German Health Minister Jens Spahn has said that Germany will receive 100 million doses of the vaccine although Germany's residents make up only 19 percent of the bloc's total population.
The EU has already signed supply deals with AstraZeneca, Sanofi and Johnson & Johnson for their experimental COVID-19 shots, and is talking with Moderna, CureVac and Novavax to secure their vaccines.